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Abstract 
Background: Evidence suggests women with breast cancer who had received chemotherapy 
experienced cognitive problems.  Although these are largely subtle deficits, they can negatively 
impact a patient‟s quality of life, ability to work and subsequent employment decisions.   
Objective: This study explored what healthcare information and support is available to help 
women understand the effects of chemotherapy on daily functioning at home and at work.  It also 
explored what information and support they would find useful as interventions. 
Methods:  Qualitative interviews were carried out with 31 patients attending a breast cancer 
clinic four months after treatment completion (phase 1); and with five oncology health 
professionals (phase 2). Fifteen women who took part in the interviews completed a short 
questionnaire on suitable interventions (phase 3). 
Results:  Participants reported problems with fatigue, low mood, memory and attention. 
Problems with remembering tasks at work were most common. Participants requested more 
information and support on cognitive difficulties. Oncology health professionals discussed the 
need for information and support for patients on managing cognitive problems. From the 
findings, four interventions and delivery modes were identified and validated.  These were: 
information and activites on cognitive strategies, help with emotional distress associated with 
cognitive difficulties and advice for families and employers. 
Conclusion: Despite mixed evidence for cognitive problems associated with chemotherapy, there 
is a need for an intervention and this may be related to managing emotional distress associated 
with perceived cognitive problems. 
Implications for practice: Nurses should include potential cognitive problems when providing 
information to patients. 
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Background 
A number of studies suggest that chemotherapy for breast cancer is associated with a number of 
neuropsychological deficits, including impairments in attention, working memory, speed of 
information processing, and executive function (e.g. planning).
1
 These impairments are reported 
during treatment and may persist more than a year after treatment.
 1
 Although recent evidence 
suggest that the effect sizes for neuropsychological tests are modest 
2 
and within the average 
range of functioning, cognitive problems can have a profound effect on patients‟ lives. Studies 
suggest that cognitive difficulties not only affect women functioning at home;
3
 but also impact 
on their quality of life and emotional well-being.
4,5
 In particular, problems with memory and 
executive functioning (assessed by neuropsychological tests) have been associated with self-
reported fatigue, depression and cognitive confusion.
6
 
 
Neuropsychological impairments have also been reported to affect work ability,
7
 and may hinder 
return to work and work-related outcomes.
8
  Work plays an important role in quality of life for 
many individuals, yet many women with breast cancer report being unable to work during or 
after treatment.
 8
  Those who do return to work, report problems in their ability to perform mental 
tasks such as concentrating, learning new things and multi-tasking.
9,10
  To date, except for two 
studies,
7,8
 most of the evidence for the effect of cognitive impairments on the quality of working 
life come from self-report studies.
10-13
  Thus, it is possible that breast cancer patients are 
sensitive to subtle changes in cognitive function that current neuropsychological test employed 
are unable to detect
1
 or that neuropsychological tests may not equate with everyday cognitive 
problems.
3
 There is moderate evidence that self-reported cognitive problems are more likely to 
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be associated with emotional distress, depression and fatigue than with neuropsychological 
functioning.
14
 These psychological factors are also reported to be associated with poor work 
ability.
15 
Regardless of the debate around the factors underlying neuropsychological impairment 
and subjective cognitive functioning among cancer patients, the perceived impact of cognitive 
functioning by women on their quality of life, particularly working life, needs to be addressed. 
 
Despite the uncertainty around the clinical significance of neuropsychological changes in breast 
cancer patients, a number of interventions have been developed.  These offer information, 
training to improve cognitive function and compensatory strategies (e.g. keeping a diary) 
following the end of treatment.  The results are mixed, with one study reporting improvements in 
cognitive function as measured by neuropsychological tests,
16 
and another reporting minimal 
evidence for improvement.
17
  The mixed results may be due to differences in the rigor of the 
study design, control groups and sample sizes. Despite the mixed findings, these studies have not 
adequately evaluated the effects of their intervention on quality of life outcomes among cancer 
patients.  In particular, as to whether these interventions improve cognitive functioning at home 
and more importantly, at work .i.e. whether they influence return to work decisions and return to 
work outcomes.   There is currently a lack of methodologically sound return to work 
interventions for breast cancer women.
18 
As women who have had breast cancer report 
experiencing cognitive problems at work following treatment,
10 
cognitive interventions could be 
targeted to improve these work-related outcomes. 
 
Before designing a cognitive intervention to improve return to work outcomes, it is important to 
carry out a needs analysis. The aim of this pilot study was to examine the need for interventions 
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related to perceived cognitive problems from the perspectives of patients and of healthcare staff.  
In particular, the study examined whether cognitive interventions were required to help patients 
manage return to work, and maintain satisfactory cognitive function at work.  
 
Method 
This was a mixed-method study consisting of three phases of data collection four months after 
the end of chemotherapy treatment: 1) semi-structured interviews with patients with breast 
cancer recruited from an NHS hospital breast cancer clinic, 2) semi-structured interviews with 
health professionals involved in care of the women participating in the study, and 3) intervention 
validation questionnaire sent to participants interviewed in phase 1. The study took place 
between September 2008 and August 2009. The study was approved by the NHS Research 
Ethics Committee. 
 
Participants  
Participants were 31 patients with breast cancer stages I-III who were taking part in a larger 
longitudinal study (with 50 women), examining the effects of chemotherapy on psychosocial 
factors, cognitive functioning and work–related outcomes (study ongoing). Patients eligible for 
the study were aged between 18 and 55 years in age, had a primary diagnosis of cancer, were 
receiving adjuvant chemotherapy and were employed at the time of diagnosis. They were 
recruited prior to their first chemotherapy appointment and were assessed on a number of 
cognitive and psychosocial measures prior to treatment (Baseline Timepoint1), mid-treatment 
(Timepoint2) and end of treatment (Timepoint3).   For this study, participants were interviewed 
after 4 months of completing their chemotherapy. Thirty-one women took part in the interviews.  
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As the researchers felt that data saturation was reached (i.e. no new information was provided in 
the last few interviews), no further participants were invited to participate.  
 
Interview procedure 
The Interviews were conducted either face-to face at the hospital or over the telephone on a day 
that was convenient. The semi-structured interview schedule was designed to explore  a) changes 
experienced in fatigue and well-being following chemotherapy; and the concerns or impact of 
these aspects on home and work life; and b) changes experienced in cognitive functioning 
following chemotherapy; and the concerns or impact of these changes on home and work life; 
and c) what healthcare information and support is currently available to help these women 
understand impact of chemotherapy and its side effects on their home and work life, and d) the 
kind of information and support they would find useful (i.e. to identify possible interventions). 
Each interview took place approximately four months after the patient had completed their 
treatment.  The interviews lasted 25 minutes and were audio-recorded and transcribed verbatim.  
 
Additional measures 
The 25-item Cognitive Failures Questionnaire (CFQ)
19 was used to assess women‟s current 
perceptions of their everyday cognitive functioning.  Participants were asked to indicate the 
frequency in which they had recently made common mistakes in attention, memory and motor 
function using a Likert scale of 0-4 (where 0 = “never” and 4 = “very often”). A total score was 
calculated ranging from 0 to 100, where higher scores indicated greater cognitive impairment. 
The CFQ provides an overall reliable picture of a patient‟s ability to cope with the demands of 
day-to-day thinking and behaving, 
20
 and has been used in previous cancer studies.
21, 22
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Depression 
The Beck Depression Inventory (BDI-II)
23
 was used to measure the severity of depressive 
symptoms.  The inventory has good reported validity and reliability particularly in the cancer 
population.
24
 The BDI-II comprises of 21 multiple choice self-report items with scores ranging 
from 0 (mild) to 3 (severe). A total score of BDI-II is calculated ranging from 0 to 63. Scores 
within the range of 16-19 are considered as mild-moderate depressive symptoms and a score of 
20 and above are considered as moderate to severe. 
 
Fatigue 
The Fatigue Severity Scale (FSS)
25
 was used to assess fatigue. It consists of 9 items around the 
interference of fatigue on physical functioning and emotional well-being. The measure has been 
used in previous cancer studies and has good reported reliability and validity.
25
 Participants are 
required to rate their level of agreement with each item on a 7-point Likert scale (where 1= 
„strongly disagree‟, and 7 =‟strongly agree‟). The total score is averaged to provide a score 
ranging from 1-7; where scores of ≥ 5.5. are considered to reflect moderate-severe fatigue. 
 
Phase 2: Oncology Health Professional Interviews 
Participants 
Five Oncology Health Professionals involved in the care of breast cancer patients were invited to 
assess the feasibility of possible interventions generated from the findings in Phase 1.  The health 
professionals were all female, aged between 30 and 45 years of age and consisted of an 
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Oncologist, a Chemotherapy Services Manager, a Deputy Senior Chemotherapy Nurse, and two 
Clinical Nurse Specialists. 
 
Interview procedure 
The health professional interviews were conducted face-to face at the breast cancer clinic or over 
the telephone. The semi-structured interview schedule was designed to a) determine the 
importance of chemotherapy-related cognitive impairment in the Oncology community, b) 
establish what healthcare information and support was currently available (by whom and when) 
on chemotherapy-related cognitive impairment and ability to work, c) establish the feasibility 
and usefulness of possible interventions as generated from the findings in Phase 1, and d) to 
identify further interventions. The health professional interviews lasted approximately 20 
minutes and were conducted by the same investigator, audio-recorded and transcribed verbatim.  
 
Phase 3: Intervention utility validation 
 
Findings from phase 1 and phase 2 were used to identify suitable interventions for cognitive 
problems and their effects at home and at work.  These were refined to include the effect on 
well-being following a literature review on current interventions to manage cognitive function in 
cancer patients.  All women who participated in the first phase were sent a report of the main 
findings from phase 1 and a short questionnaire outlining types of interventions that could be 
offered . These were sent to the women two-six months after their interview.  Participants were 
asked to rate the usefulness of each of these using a Likert scale of 1-5 (where 1 = not useful at 
all and 5 = very useful). In addition participants were asked to indicate who they thought should 
 33 
provide these interventions (e.g. breast cancer nurse, cancer charity, employers).  Fifteen women 
(45 %) completed and returned the short questionnaire. 
 
Data Analyses 
 
Qualitative data 
Interview data from phase 1 and 2 were analysed by a combination of qualitative and 
quantitative content analyses
26-28 
by an independent researcher who was not involved in the data 
collection but was closely involved in all stages of study design and is also carrying out similar 
research to this study.  This was due to  interviewer becoming ill following data collection.  First, 
quantitative content analyses was used to quantify and generate frequencies on interviewees‟ 
statements on types of 1) cognitive changes experienced 2) information received from healthcare 
professionals and 3) information/support required.  This process is widely used in qualitative 
research
29, 30
 to answer pre-defined questions. A sub-sample of transcripts was read and 
preliminary codes were formulated to create an initial coding scheme. The remaining transcripts 
were read and coded. During this iterative process, new codes were added if novel data emerged 
to generate a more precise coding scheme. The consistency of the coding was re-checked by the 
lead author who independently coded all transcripts to ensure the reliability. Descriptive 
statistical analyses, namely frequencies and percentages were applied. For qualitative content 
analysis, relevant comments from the transcripts were highlighted and quotations were excerpted 
to illustrate codes. This enabled a deeper understanding of the context of codes (see Table 1).  
 
Questionnaire data 
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Data were analyzed using SPSS version 16.0. For phase 1, data on self-report cognitive 
functioning, fatigue and depression were analyzed using repeated measures ANOVA or the 
Friedman Test to compare scores across T1 (baseline), T2 (mid-treatment) and T3 (end of 
treatment).  Correlations were run to examine the relationship between these variables. 
Descriptive statistics were used to summarize the findings from phase 3. 
 
Results 
Findings from phase 1 
Characteristics of the patients 
Table 2 outlines details of the participants with breast cancer.  The mean age was 47 years (range 
34-62 years). Seventeen (52%) participants had a lumpectomy and 16 (48%) had a mastectomy. 
For chemotherapy, regimens included fluorouracil, epirubicin and cyclophosphamide (FEC); 
fluorouracil, epirubicin, cyclophosphamide and docetaxel (FEC-T); cyclophosphamide, 
methotrexate, and fluorouracil (CMF), or docetaxel and cyclophosphamide. Twenty (61%) 
participants reported their job as manual work and 13 (39 %) reported their job as non-manual. 
Prior to chemotherapy 18 (58%) participants were pre-menopausal or peri-menopausal and 13 
(42%) participants were postmenopausal. Prior to diagnosis 26 (84%) participants were working 
and four (13%) were on sick leave. At end of chemotherapy (4 months after treatment), 17 (57%) 
were working and 13 (43%) were still on sick leave.  The Friedman test showed a statistically 
significant increase in depressive symptoms from baseline to after treatment 2 (2, n=24) = 9.13, 
p ≤ 0.01), but only a near statistically significant increase in perceived cognitive problems across 
the study period 2 (2, n=24) = 5.36, p = 0.07).  For fatigue, repeated measures ANOVA 
revealed a significant increase in self-report fatigue across the study period [F(2, 42) = 11.55, p ≤ 
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0.001, partial eta squared = 0.36].  Spearman‟s rho correlation analyses revealed no statistically 
significant correlation between these three variables at baseline.  At T2 and T3, subjective 
cognitive functioning positively correlated with depressive symptoms (rs = 0.54 and 0.82 
respectively, p<.01) and with fatigue (rs = 0.66 and 0.66 respectively, p<.05). 
 
Psychosocial and cognitive changes experienced at home and at work 
The majority of women interviewed (28/31) reported experiencing fatigue, low mood and 
cognitive problems following chemotherapy. For cognitive problems memory, concentration and 
attention were highlighted. Over half the participants (19/28) thought chemotherapy treatment 
and fatigue contributed to their cognitive problems. More than half the participants who were 
working (12/17), reported having frequent problems with remembering tasks at work: 
 
I would flit from one job to another…I still find now that if I‟ve remembered I‟ve got to do 
something, I try to do it there and then, because I think I‟m going to forget to do it (Participant 30). 
 
I‟ve got a girl that works really closely with me… she‟ll help me decide what it is that we 
need… and we write it all down.  (Participant 10). 
 
Five out of 13 women who had not yet returned to work, questioned their confidence in their 
ability to return to work or to carry out work tasks as a result of the cognitive changes they were 
experiencing: 
 
Its [problems with memory]  made me anxious about going back to work.  And that‟s why I‟ve 
been very clear about only doing one day a week for the first month.  (Participant 7). 
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Not all that confident…At work, you‟re telephoning and using the computer at the same time. So 
I‟m … apprehensive about that. (Participant 23). 
 
Managing fatigue and emotional distress associated with not being able to carry out normal 
cognitive tasks also concerned women with regard to returning to work.   
 
Available information on cancer treatment and symptoms, side effects and work 
All women received information (in a leaflet or verbal) regarding physical side effects and 
effects of fatigue associated with treatment.  They also received some information on 
psychological well-being and general emotional distress associated with cancer diagnosis and 
treatment. In contrast, only nine (27%) women received information (in a leaflet or verbal) about 
memory and concentration problems from their oncology team; of which five were patient-led 
discussions. Only two women were told how this might affect them in their job. Both of these 
were patient-led discussions. Only three women received information about cancer and work. 
The participants discussed how lack of information can negatively affect well-being and 
recovery. One participant commented that if the researcher had not told her about the possibility 
of cognitive problems, she would have thought she was going senile. Another participant noted: 
 
 I think it would have been useful to know that your brain will still function but you‟ve got to 
narrow its activity a little bit…Perhaps, if someone had told me that, because you feel as if you‟re 
losing that faculty. (Participant 6). 
 
A third of participants felt that advice on working during treatment was not clear, and that more 
should be done to advise patients on this. 
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It would be useful to have a leaflet which would encourage people to stay, if not full-time 
work, at least part-time work, and to explain to people the [cognitive] side effects….and 
that they can do this and that…. If you raise awareness, and at the same time encourage 
people that it‟s not that bad, and there‟s no need to just stay at home. (Participant 2). 
 
Type and delivery of intervention 
A broad question was asked on what information or help participants would like to help them 
manage their cancer and treatment better. In total, 7 types of interventions were identified from 
the transcripts. The most frequent was for more information and help with managing cognitive 
changes associated with chemotherapy (19/33 participants), and its affect on work (7/17 
participants). Participants felt these may help to alleviate distress as they would know what to 
expect. Over half of these participants (55%) also suggested a cognitive activity (e.g. crossword 
puzzles and word searches) to keep the brain active would be useful. The remaining suggestions 
were for information for family, colleagues and employers on cognitive problems and how best 
to support the patient and information on return to work and finances. A third felt the 
intervention (e.g. information) should be delivered by their breast cancer nurse or by cancer 
charities to include as part of their rehabilitation/support.  Less than half of the participants 
thought an intervention on compensatory strategies (e.g. use of diaries) were required as most 
were already using such strategies. 
 
Findings from phase 2: Interviews with oncology health professionals 
All five participants were aware of  breast cancer patients reporting psychosocial problems such 
as fatigue and distress  and  problems with memory and attention during their chemotherapy 
treatment.  All participants felt that the most significant impact of fatigue and cognitive problems 
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would be at work, and which may exacerbate their distress and ability to cope with the 
difficulties experienced .  
 
[Work] affecting their thought process or it‟s affecting their short term memory then it 
makes their day so much harder, because they‟re having to double-check everything 
they‟re doing. (Clinical Nurse Specialist). 
 
Participants agreed there was a lack of information, support and advice to patients on cognitive 
difficulties they may experience a result of their diagnosis and treatment. They also agreed there 
was a need to provide more staff-led information on what cognitive problems patients may 
experience at home and at work.  Participants were undecided about the type of interventions 
beneficial to patients, most felt information leaflets were sufficient. Only the consultant felt there 
was a need for an activity-related intervention for cognitive problems.  Work was a strong theme 
among participants and generated the most discussion. One view was that work itself could be an 
effective intervention. 
 
If they‟re working when they‟re on the treatment, probably they‟re using their brains more 
frequently anyway. Maybe the exercising of their brains is doing them good because they‟re 
carrying on working. (Deputy Senior Chemotherapy Nurse). 
 
 
Findings from Phase 3: Intervention utility validation 
From the findings from phases 1 and 2 interviews and from a literature review were used to 
identify suitable interventions for perceived cognitive difficulties and their effects at home and at 
work. A summary of the findings were sent to all the participants with breast cancer and together 
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with a questionnaire outlining the interventions arsing from all interviews and from the literature 
review. Fifteen women completed and returned the questionnaire.  All respondents verified that 
the summary of the findings accurately reflected their views. However, there was no dominant 
intervention that emerged from the questionnaire. Table 3 shows that the majority of women 
confirmed that an assessment of their cognitive functioning before and after treatment would be 
useful.  Activities to help them manage their cognitive problems would also be useful. Equally, 
most of the women felt that help with coping with emotional stress and help in how to tell others 
about their cognitive problems would be beneficial.  Table 4 shows that most participants felt 
any of these interventions could be delivered as information in a form of a leaflet, as a website 
activity or in the form of support from the oncology team.  Intervention activities for maintaining 
cognitive function were also preferred by the majority of participants (10/14, 71%) compared 
with activities to compensate for cognitive problems experienced (8/13, 62%). 
 
Discussion 
Drawing from multiple perspectives this study presents novel information about the type of 
interventions required to support breast cancer patients manage the perceived cognitive effects of 
chemotherapy at home and at work.  It also highlights patients‟ needs for intervention on 
managing emotional distress associated with perceived cognitive problems at home and in the 
workplace.  
 
Overall, the study found that perceived cognitive functioning is a concern for breast cancer 
women. The majority of the participants thought that chemotherapy treatment and fatigue 
contributed to their cognitive problems, with over half of those working indicating that they 
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experience frequent problems remembering tasks at work. While evidence regarding the true 
impact of chemotherapy on cognitive functioning remains mixed,
1,2
 it is clear that for many 
breast cancer patients there is a perceived impact on their cognitive functioning and they believe 
that this effects their work ability and their confidence to do their job well.  This is supported by 
Wefel
7
 who found that women with breast cancer demonstrating cognitive decline on objective 
neuropsychological tests also reported experiencing greater difficulty at work shortly after the 
end of chemotherapy.  Research into the relationship between cognitive functioning and work 
ability is still its infancy and more empirical research is required to examine the relationship 
between treatment, cognitive functioning, psychosocial factors and work ability. 
 
This study found that there is a lack of information, advice and support available regarding work 
and managing side effects at work; as well as lack of information on cognitive functioning.  Less 
than a third of participants in this study received information about memory or concentration 
problems while undergoing chemotherapy. Furthermore, for those who did receive information 
over half reported that this discussion was patient-led. Interestingly, all oncology health 
professionals interviewed indicated that they believed there was a lack of information available 
to breast cancer women in on cognitive difficulties they could experience. 
 
The findings from this study provide a basis to drive further intervention research. It also 
provides preliminary data  for the content and delivery mechanism for future interventions. 
When interviewed and surveyed, participants indicated that an assessment of their cognitive 
function would be useful prior to, and at the end of chemotherapy.  While it may not be feasible 
to offer this to patients, a self-assessment could be introduced at the end of treatment when 
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patients are planning on returning to work.  This would give them a useful indication as to the 
work adjustments they may need from their employers. Participants also wanted a cognitive-
based activity intervention.  It is not known whether such activities would improve 
neuropsychological impairments, particularly as the evidence for such impairments are low to 
moderate at best.
2
 However, it is possible that these may help to improve confidence in 
managing cognitive tasks, which in turn may improve subjective reports of cognitive problems.  
Therefore any cognitive intervention would need to rigorously assess these possible outcomes.  
Participants indicated requiring support with emotional problems associated with the cognitive 
problems they are experiencing.  Emotional distress has been associated with self-reported 
cognitive problems.
14
  In this study, although self-report cognitive problems did not significantly 
decline during chemotherapy treatment, it correlated with both depressive symptoms and fatigue 
as treatment progressed. While it not yet clear if subjective cognitive problems reflect emotional 
distress rather than actual neuropsychological impairments (i.e. impaired ability to think clearly 
is a possible symptom of depression), and which may exist pre-treatment, both subjective 
cognitive problems and emotional well-being are reported as to affect work ability.
31
 suggest that 
even if subjective cognitive problems do not appear to be based on neuropsychological 
compromise, these factors need to be addressed.  Therefore identifying and reducing the 
emotional distress associated with subjective cognitive functioning should be a key outcome 
measure for any intervention.   
 
This study was not without limitations. First, this study was an exploratory study and therefore 
while the sample recruited was relatively narrowly defined in terms of diagnosis and time 
interviewed, we did not control for type of chemotherapy drug taken, surgery variables or 
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occupation.  Second, the participants were recruited from one hospital and therefore the nature of 
the information and advice available from healthcare staff may be biased to that provided by the 
particular Trust. It is also possible that the women taking part in this study were self-selected due 
to experiencing problems in cognitive function.  However, all women agreed to participate prior 
to the start of chemotherapy and reported not experiencing problems at that time.  Nevertheless, 
there could still be an issue of priming i.e. knowledge about chemotherapy-associated cognitive 
problems may have resulted in influencing perception of cognitive problems.
32 
 Effort was made 
to reduce this possible bias by telling the patients that the study focused on work experiences and 
other psychosocial factors as well as cognitive functioning.  However, as there was no control 
group it is not known to what extent this minimised priming and therefore the results of this 
study should be interpreted with caution. Another limitation of the study is that we did not 
include a healthy control group to compare the participants score on the CFQ. However, the 
inclusion of a healthy control group would not take into account potential disease and treatment 
related factors.
33
 
 
 
Conclusion 
This study identified that breast cancer women perceive chemotherapy to impact upon their 
cognitive functioning and their ability to work. Interventions such as self-assessment of cognitive 
function; information and support on cognitive problems, cognitive activities and emotional 
distress and advice for families and employers were considered to be most important by the 
participants. Based on the findings from this study, further research in interventions are 
recommended.  Intervention studies demand significant resource investments both in terms of 
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funding and researcher and participant time. It is important that researchers consider the needs, 
as identified by patients and oncology professionals, and use these as a platform to integrate and 
test sound psychological theories and interventions.  It is hoped that these findings provide a 
platform for need-driven intervention studies in the future.  
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Table 1: Summary of Themes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase 1: Participants With Breast Cancer 
Awareness of 
cognitive problems 
Problems with memory and attention  
Problems with remembering tasks at work 
Low confidence in managing problems at work 
Information and 
support received 
Lack of information and support on cognitive problems 
Impact on well-being and recovery 
Information and 
support required 
Activities that help compensate of maintain cognitive 
problems 
Work-related support for cognitive problems 
Written information about cognitive problems 
Help with coping with emotional distress and talking about 
cognitive problems with others 
Phase 2: Oncology Health Professionals 
Awareness of 
cognitive problems 
Being told by patients 
Cognitive problems affecting work 
Information and 
support  
Lack of information and support available 
Work as an intervention 
Information leaflets 
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Table 2. Demographic Data and Mean Scores on Self-Report Cognitive Functioning, Depressive Symptoms and Fatigue (n=31)  
 
 
 
 
 
 
 
 
 
 
 aFriedman anayses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Baseline (T1) Mid-Chemotherapy 
(T2) 
1-4 Months Post 
Chemotherapy (T3) 
P Value 
Age, mean (SD) 47 (6) - - - 
Manual occupation % (n) 61 (20) - - - 
Sick leave % (n) 13 (4) 63 (19) 43 (13) - 
Cognitive problems, mean (SD) 35.33 (11.63) 43.00 (15.76) 42.42 (17.84) .07
 a
 
Depressive symptoms, mean (SD) 11.17 (6.50) 14.50 (7.75) 15.38 (9.29) .01
 a
 
Fatigue, mean (SD) 4.11 (0.91) 4.91 (1.14) 5.23 (1.22) .001 
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Table 3. Interventions Reported as „Quite a Bit Useful‟ to „Very Useful‟ to Help Cognitive 
Function at Home or at Work by Breast Cancer Women (n=15) 
 
 Home-related 
 
N (%) 
Work-related 
 
N (%) 
Coping with emotional stress associated with 
cognitive problems 
15 (100) 13 (93) 
Assessment of cognitive function during and after 
treatment 
15 (100) 13 (93) 
Activities to help manage or compensate for cognitive 
problems 
14 (100) 14 (93) 
How to tell others about cognitive problems and what 
to tell them 
13 (93) 14 (93) 
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Table 4. Types of Interventions and Delivery Methods Reported as „Somewhat Useful‟ to 
„Very Useful‟ by Breast Cancer Women (n=15) 
 
 
 Activities that 
maintain cognitive 
function 
N (%) 
Activities that 
compensate for 
cognitive problems 
 
N (%) 
Leaflet 13 (92) 13 (92) 
Website 12 (86) 12 (86) 
Oncology team 13 (92) 13 (92) 
Practical classes 10 (71) 8 (62) 
Telephone support 8 (62) 8(62) 
 
 
